Physician profile
Amy E Andersen
NPI 1932169778
$3,164.84
in general payments reported to CMS, 2019-2025
26 companies · $21.35 in 2025
The $21.35 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $503 · 2021: $1,232 · 2022: $50.06 · 2023: $188 · 2024: $148 · 2025: $21.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $421.43 | 2019-2024 | Eliquis, Camzyos |
| Pfizer INC. | $330.56 | 2019-2021 | |
| Abbvie INC. | $308.28 | 2021-2025 | |
| Allergan, INC. | $297.35 | 2019-2020 | |
| Lilly USA, LLC | $255.36 | 2019-2021 | |
| Amgen INC. | $221.55 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $179.36 | 2019-2021 | |
| Astellas Pharma US INC | $155.88 | 2019-2021 | |
| Novo Nordisk INC | $151.82 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $148.90 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $124.37 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.71 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $86.13 | 2021 | |
| Jazz Pharmaceuticals INC. | $73.96 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.19 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $52.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.06 | 2021 | |
| Exeltis, USA INC. | $29.98 | 2020 | |
| Daiichi Sankyo INC. | $20.84 | 2021 | |
| Therapeuticsmd, INC. | $18.88 | 2021 | |
| Ironwood Pharmaceuticals, INC | $17.24 | 2019 | |
| Amarin Pharma, INC. | $16.92 | 2021 | |
| Celgene Corporation | $15.52 | 2024 | Camzyos |
| Merck Sharp & Dohme LLC | $12.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.67 | 2019 | |
| Glaxosmithkline, LLC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Andersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.